Novel Drugs Targeting Transthyretin Amyloidosis
Author:
- 25 January 2014
- journal article
- review article
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 11 (1) , 50-57
Abstract
Transthyretin amyloidosis (ATTR) is either a hereditary disease related to a mutation in the transthyretin gene that leads to neuropathy and/or cardiomyopathy or an acquired disease of the elderly that leads to restrictive cardiomyopathy. The prevalence of this disease is higher than once thought and awareness is likely to increase amongst physicians and in particular cardiologists. Until recently there have been no treatment options for this disease except to treat the heart failure with diuretics and the neuropathy symptomatically. However, there are several emerging pharmacologic therapies designed to slow or stop the progression of ATTR. This article reviews novel therapeutic drugs that work at different points in the pathogenesis of this disease attempting to change its natural history and improve outcomes.Keywords
This publication has 62 references indexed in Scilit:
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- A New Era in the Treatment of Amyloidosis?New England Journal of Medicine, 2013
- Senile Systemic Amyloidosis: Clinical Features at Presentation and OutcomeJournal of the American Heart Association, 2013
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences, 2012
- Green tea halts progression of cardiac transthyretin amyloidosis: an observational reportClinical Research in Cardiology, 2012
- Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosisBlood, 2011
- Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formationFEBS Letters, 2011
- Antibodies to human serum amyloid P component eliminate visceral amyloid depositsNature, 2010
- Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse modelsJournal of Translational Medicine, 2010
- Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice modelThe FASEB Journal, 2006